<DOC>
	<DOCNO>NCT00041938</DOCNO>
	<brief_summary>The purpose study determine two treatment , Warfarin aspirin , good prevent death stroke patient poor heart function . We transition sub-analysis part WARCEF patient data . The study recently complete data analysis Primary Aim . All randomized patient complete follow . All study related procedure per protocol complete . We extension phase study obtain patient data address aim study . No new procedure perform data already place site collect ( EKG echocardiograms ) . The aim study extension : - To assess progression cardiac dysfunction time among heart failure patient - To correlate prognosis cardiac dysfunction</brief_summary>
	<brief_title>Warfarin Versus Aspirin Reduced Cardiac Ejection Fraction ( WARCEF ) Trial</brief_title>
	<detailed_description>Warfarin proven effective patient ischemic heart disease , especially reduction stroke , death re-infarction follow myocardial infarction , reduction stroke atrial fibrillation . Warfarin promise unstudied intervention patient cardiac failure . This randomized , double-blind , multi-center study define optimal antithrombotic therapy patient cardiac ( heart ) failure patient low ejection fraction ( EF ) . EF proportion leave ventricular volume empty systole . It reliably measure leave ventricular systolic function . With rapidly increase number elderly patient heart failure , study important public health implication . The study determine two commonly use treatment Warfarin , anticoagulant , aspirin , drug affect platelet function well prevent death stroke patient low ejection fraction .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion Criteria Cardiac EF &lt; =35 % radionuclide ventriculography , leave ventriculography quantitive echocardiographic measurement echocardiographic Wall Motion Index &lt; =1.2 , within three month enrollment . The patient 's clinical cardiac state enrollment similar state time qualify echocardiogram . The qualifying leave ventricular function measurement must obtain least three month MI , coronary bypass grafting , PTCA , least one month pacemaker insertion . Patients scheduled mitral valve repair qualify echo surgery . Modified Rankin score &lt; =4 . Patient must take ACE inhibitor . If intolerant ACE inhibitor , patient must angiotensin II receptor blocker hydralazine nitrate . Patient able follow outpatient protocol ( require monthly blood test clinic visit every four month duration study ) available telephone . Patient understand purpose requirement study , make him/herself understood , provide informed consent . Patients recent stroke TIA within twelve ( 12 ) month eligible include recent stroke ( RS ) subgroup . Chronic CHF patient ( NYHA I * IV ) admit hospital randomized prior discharge patient stable , take oral medication 24 hour ambulatory time discharge . Stable New York Heart Association Class IV patient eligible randomization . Exclusion Criteria The presence follow unequivocal cardiac source embolism : chronic paroxysmal AF , mechanical valve , endocarditis , intracardiac mobile pedunculated thrombus , valvular vegetation . Cyanotic congenital heart disease , Eisenmenger 's syndrome . Decompensated heart failure . Cardiac surgery , angioplasty , MI within past 3 month prior randomization . A contraindication use either warfarin aspirin , e.g . active peptic ulcer disease , active bleeding diathesis , platelet &lt; 100,000* , hematocrit &lt; 30 , INR &gt; 1.3 ( warfarin ) , clot factor abnormality increase risk bleeding , alcohol substance abuse , severe gait instability , cerebral hemorrhage , systemic hemorrhage within past year , severe liver impairment ( AST &gt; 3x normal* , cirrhosis ) , condition require regular use nonsteroidal antiinflammatory agent , allergy aspirin warfarin , uncontrolled severe hypertension ( systolic pressure &gt; 180 mm Hg diastolic pressure &gt; 110 mm Hg ) , positive stool guaiac attributable hemorrhoid , creatinine &gt; 3.0* . *on recent test do within 30 day prior randomization Patient need continue therapy intravenous heparin low molecular weight heparin specific antiplatelet agent . Dementia psychiatric physical problem prevents patient follow outpatient program reliably . Comorbid condition may limit survival less five year . Pregnancy , female childbearing potential sterilize use medically accept form contraception* ( see procedure manual ) . *A pregnancy test require woman childbearing age . Enrollment another study would conflict WARCEF . Hospitalization new diagnosis onset CHF within past one month carotid endarterectomy pacemaker insertion within past one month prior randomization . Person 18 year age .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>heart disease</keyword>
	<keyword>stroke</keyword>
	<keyword>ischemic heart disease</keyword>
	<keyword>myocardial infarction</keyword>
	<keyword>atrial fibrillation</keyword>
	<keyword>low ejection fraction</keyword>
	<keyword>cardiac failure</keyword>
	<keyword>aspirin</keyword>
	<keyword>Warfarin</keyword>
	<keyword>anticoagulant</keyword>
</DOC>